### Landmark Shift in U.S. Drug Policy: Trump Directs Rescheduling of Marijuana In a significant move for U.S. drug policy, President Donald Trump signed an Executive Order on December 18, 2025, directing the Attorney General to expedite the rescheduling of marijuana from a Schedule I to a Schedule III controlled substance. This change reflects a growing recognition of the medical benefits of cannabis while maintaining restrictions on recreational use. The rescheduling process, which began in October 2022, aims to facilitate medical research and potentially reshape the cannabis industry across the nation. This executive order marks one of the most dramatic shifts in federal cannabis policy in decades, aligning marijuana with substances that have accepted medical uses, such as certain painkillers and hormones [https://www.thefdalawblog.com/2025/12/e-o-directs-ag-to-complete-marijuana-schedule-iii-rescheduling, https://www.mondaq.com/unitedstates/cannabis-hemp/1723458/trumps-signs-executive-order-to-reschedule-cannabis-a-dramatic-shift-in-federal-cannabis-policy]. ### Structure of the Executive Order and Its Implications 1. **Rescheduling Process**: The Executive Order mandates the Department of Justice to expedite the reclassification of marijuana, which could lead to reduced federal restrictions and increased access for medical research [https://www.jdsupra.com/legalnews/executive-order-directing-doj-to-9864924]. 2. **Impact on the Cannabis Industry**: The reclassification is expected to ease tax burdens on cannabis businesses and open up new avenues for research and development in the medical field [https://www.jdsupra.com/legalnews/what-trump-s-executive-order-to-4425755]. 3. **State-Level Reactions**: Following the announcement, various states, including Tennessee and New Mexico, have begun to call for reforms in their own cannabis policies, reflecting a broader shift in public and governmental attitudes towards marijuana [https://3bmedianews.com/trump-executive-order-sparks-tennessee-calls-for-marijuana-reform, https://www.tricityrecordnm.com/articles/new-mexico-cannabis-industry-cheers-trumps-rescheduling-order]. ### Supporting Evidence and Data - **Executive Order Details**: The order titled "Increasing Medical Marijuana and Cannabidiol Research" emphasizes the need for further studies on cannabis, which has been historically restricted under federal law [https://www.jdsupra.com/legalnews/marijuana-rescheduling-pending-despite-2834765]. - **Market Reactions**: Analysts predict that the rescheduling could positively impact cannabis stocks and reshape the regulatory landscape, as businesses anticipate a more favorable environment for operations [https://finance.yahoo.com/news/trump-orders-marijuana-reclassification-means-132600631.html]. - **Public Sentiment**: Polls indicate a growing acceptance of cannabis use for medical purposes among the American public, which may influence future legislative actions at both state and federal levels [https://www.lemonde.fr/en/international/article/2025/12/19/trump-orders-marijuana-reclassified-as-a-less-dangerous-drug_6748650_4.html]. ### Conclusion: A New Era for Cannabis Policy The Executive Order signed by President Trump represents a **historic shift** in U.S. drug policy, with the potential to reshape the landscape of cannabis regulation and research. Key takeaways include: 1. **Rescheduling Marijuana**: Moving marijuana to Schedule III could facilitate medical research and reduce federal restrictions [https://www.gaffneyledger.com/articles/trump-reclassifies-marijuana-to-schedule-iii]. 2. **Industry Transformation**: The cannabis industry is poised for significant changes, including potential tax relief and increased investment opportunities [https://www.jdsupra.com/legalnews/prohibition-to-prescription-what-trump-2044964]. 3. **State-Level Reforms**: States are likely to respond to this federal shift with their own reforms, reflecting changing public attitudes towards cannabis [https://www.jdsupra.com/legalnews/bye-bye-280e-new-executive-order-8812757]. This executive order not only marks a pivotal moment in cannabis policy but also sets the stage for ongoing discussions about drug reform in the United States.